This case chronicles the challenges of creating an advanced tissue bank service to accelerate the research and development procedures of pharmaceutical and biotechnology companies worldwide. Asterand's two major challenges called for achieving a standardized approach to gathering tissue samples in hospitals all over the world and achieving the maximum possible quality of tissue samples sent Amgen, to their main customer. Despite the identified demand for high-quality tissue samples, Asterand was experiencing multiple quality control problems in their processes and procedures.
Tissue samples delivered, tagged incorrect or were being packaged poorly at the unsuitable time or incorrect place. Furthermore, there were also quality at the incorrect time and incorrect place. In addition, there were dilemma’s concerned with RNA evaluation of the samples, which was a vital determinant in the usability of the tissue sample for development and research of drugs and new therapies. The head of pathology at the Amgen’s California facility that was threatening to eliminate their present order and convey the failure of Asterand to all firm employees, which might have had a disastrous ripple effect on the other side of the industry and likely destroyed chances for any future orders with Asterand. Asterand would have been at risk of going broke and losing investors and would not have really been able to procure contracts with customers if this happened.
PUBLICATION DATE: October 29, 2012 PRODUCT #: W12286-PDF-ENG
This is just an excerpt. This case is about INNOVATION & ENTREPRENEURSHIP
Related Case Solutions & Analyses:
Negotiation Exercise on Tradeable Pollution Allowances: Group Utility 3
ACTC Customer Service Department
Montecito State College
Vanguard Group Inc. (B)
Brink’s Company: Activists Push For A Spin-Off
China’s Renminbi: “Our Currency, Your Problem”?
Levi Strauss & Co. (C)
Silkor Laser Medical Center
A-CAT Corp.
Ajax Petroleum
